H-02 · Standards Field: IHPSO Health Standards
Biomarkers & Laboratory Data
Requirements for responsible use, interpretation and communication of biomarkers and laboratory data within professional scope.
Purpose
Biomarkers and laboratory data can provide valuable information about biological processes, pathological processes or responses to exposures and interventions, but they are easily overinterpreted. A biomarker is not automatically a direct clinical outcome describing how a person feels, functions or survives. H-02 establishes a shared IHPSO standard for how Professionals, Providers and Organisations contextualize measurements, communicate their limitations and distinguish measurement, interpretation and diagnosis. In particular, the standard is intended to prevent individual values, reference ranges, experimental markers or algorithmic interpretations from being presented without sufficient context as confirmed diagnosis, prognosis or clinical benefit.
Scope
H-02 applies to the professional use and communication of biomarkers, laboratory values and related measurement data within the IHPSO Health Standards Field. It covers measurements and measurement uncertainty, reference ranges, biological variability, single measurements and trends, context, clinical and experimental biomarkers, surrogate endpoints, algorithmic interpretations, and the boundaries of interpretation, diagnosis and referral. The standard does not establish universal reference ranges, replace clinical laboratory medicine or determine who may perform diagnostic or medical interpretation in a particular jurisdiction. Those questions are governed by U-02 Scope of Practice and applicable legal, professional and organizational requirements.
Requirements
- Professionals must treat measurement, interpretation and diagnosis as distinct levels. A measurement is not automatically an interpretation, and an interpretation is not automatically a diagnosis.
- A single biomarker or laboratory value must not be presented without sufficient context as proof of health, disease, dysfunction or need for treatment.
- Reference ranges must be understood in the context of the method used, laboratory, population and clinical or professional purpose; “within range” does not automatically mean healthy and “outside range” does not automatically mean diseased.
- Population reference intervals and within-person change are different interpretive concepts. Population reference interval ≠ individual change.
- A reference interval is not automatically a diagnostic decision threshold or treatment target. Such thresholds may be defined separately depending on the test, purpose, population and guideline.
- Measurement uncertainty, analytical variation and relevant biological variation must be considered where they may materially affect interpretation of a value.
- Pre-analytical conditions such as timing, fasting status, physical activity, body position, sample collection, storage or transport may materially affect results and interpretation and should be considered where relevant.
- Analytical validity and clinical validity must be distinguished. A test can measure reliably without automatically establishing the clinical meaning of the result for a particular purpose.
- Single measurements and trends over time must be distinguished. A trend may be informative but does not automatically remove measurement error, confounding or missing clinical context. Trends should be treated as comparable only where the measurement method, units and relevant measurement conditions are sufficiently comparable.
- Professionals may interpret biomarkers individually only to the extent supported by their actual competence, role, applicable rules and specific context.
- Experimental, proprietary or insufficiently validated biomarkers must remain identifiable as such and must not be equated with established diagnostic tests or validated clinical endpoints.
- A biomarker is not automatically a validated surrogate endpoint. Surrogate validity is context-of-use specific and must not automatically be transferred to other interventions, populations or outcomes. A better marker is not automatically a better outcome.
- Direct clinical outcomes concern outcomes meaningful to people, including how people feel, function or survive (feel · function · survive). Biomarkers must not be equated with these outcomes without adequate validation.
- Changes in a biomarker or surrogate measure must not automatically be communicated as demonstrated clinical benefit, disease prevention or improved lifespan.
- Biomarker relevance must match the specific claim. Population, measurement method, timing, intervention, outcome and context of use should be considered when transferring evidence.
- Algorithmic or proprietary scores, automated interpretations or laboratory comments must not be treated as clinically validated or infallible conclusions solely because of their technical presentation. Proprietary score ≠ validated clinical interpretation.
- Professionals must distinguish data description from action recommendations. An individualized recommendation based on laboratory data may trigger additional competence or scope requirements.
- Abnormal, unexpected or potentially relevant measurements must not be dismissed. Where appropriate professional assessment is outside scope, the boundary must be disclosed and referral used according to the situation.
- Where red flags or possible acute danger are present, IHPSO Referral Levels and applicable local emergency procedures apply; H-02 does not constitute medical triage.
- Health claims based on biomarkers must also comply with H-01 Health Information & Claims and U-03 Evidence & Scientific Communication.
- Where an IHPSO Evidence Classification is used, it must apply to a specific biomarker or outcome claim and must not be assigned broadly to the biomarker itself.
Evidence classification
Not assigned at standard level
Justification
H-02 contains normative Professional Requirements together with scientific principles applying to different biomarkers, measurement methods and outcomes. Assigning a single Evidence Classification to the entire standard would inappropriately combine distinct claim-evidence relationships. Under the IHPSO Health Standards Architecture 1.0, Evidence Classification is used only where scientifically applicable and on a claim-specific basis. Specific biomarker, surrogate or outcome claims may be classified separately.